Premium
Should prophylactic granulocyte‐colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide‐based therapy?
Author(s) -
Mateos MaríaVictoria,
GarcíaSanz Ramón,
Colado Enrique,
Olazábal Juan,
SanMiguel Jesús
Publication year - 2008
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2007.06946.x
Subject(s) - lenalidomide , neutropenia , dexamethasone , medicine , multiple myeloma , granulocyte colony stimulating factor , oncology , chemotherapy , surgery , gastroenterology
Summary Lenalidomide combined with dexamethasone has significant clinical activity in the treatment of multiple myeloma (MM). In previous clinical trials lenalidomide‐induced neutropenia was a frequent side‐effect, often leading to treatment delays and dose reductions. We describe three MM patients treated with lenalidomide plus dexamethasone, which developed grade 3/4 neutropenia during the initial cycles, but without serious infection. Administration of granulocyte‐colony stimulating factor (G‐CSF) for 3 d prevented further neutropenia, treatment delays, dose reductions, or infectious complications during the following cycles. Consequently, G‐CSF could be effective in preventing further neutropenia‐related complications without compromising treatment efficacy in MM patients with lenalidomide‐induced neutropenia.